{"doc_id": "32425222", "type of study": "Therapy", "title": "", "abstract": "Repurposing chlorpromazine to treat COVID-19: The reCoVery study.\nThe ongoing COVID-19 pandemic has caused approximately 2,350,000 infections worldwide and killed more than 160,000 individuals.\nIn Sainte-Anne Hospital (GHU PARIS Psychiatrie & Neuroscience, Paris, France) we have observed a lower incidence of symptomatic forms of COVID-19 among patients than among our clinical staff.\nThis observation led us to hypothesize that psychotropic drugs could have a prophylactic action against SARS-CoV-2 and protect patients from the symptomatic and virulent forms of this infection, since several of these psychotropic drugs have documented antiviral properties.\nChlorpromazine (CPZ), a phenothiazine derivative, is also known for its antiviral activity via the inhibition of clathrin-mediated endocytosis.\nRecentin vitro studies have reported that CPZ exhibits anti-MERS-CoV and anti-SARS-CoV-1 activity.\nIn this context, the ReCoVery study aims to repurpose CPZ, a molecule with an excellent tolerance profile and a very high biodistribution in the saliva, lungs and brain.\nWe hypothesize that CPZ could reduce the unfavorable course of COVID-19 infection among patients requiring respiratory support without the need for ICU care, and that it could also reduce the contagiousness of SARS-CoV-2.\nFor this purpose, we plan a pilot, multicenter, randomized, single blind, controlled, phase III therapeutic trial (standard treatment vs. CPZ+standard treatment).\nThis repurposing of CPZ for its anti-SARS-CoV-2 activity could offer an alternative, rapid strategy to alleviate infection severity.\nThis repurposing strategy also avoids numerous developmental and experimental steps, and could save precious time to rapidly establish an anti-COVID-19 therapy with well-known, limited and easily managed side effects.\nCopyright \u00a9 2020 L'Enc\u00e9phale, Paris. Published by Elsevier Masson SAS.\nAll rights reserved.\n", "Evidence Map": {"Enrollment": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 36, "end": 44}, {"term": "respiratory support", "negation": "affirmed", "UMLS": {}, "start": 107, "end": 126}, {"term": "for ICU care", "negation": "negated", "UMLS": {}, "start": 144, "end": 156}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Repurposing chlorpromazine to treat COVID-19 : The reCoVery study .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 36, "end": 44}], "Intervention": [{"term": "Repurposing chlorpromazine", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 26, "has_chemical": [{"text": "chlorpromazine", "maps_to": "C0033229:Prochlorpromazine", "start": 12, "end": 26}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "OBJECTIVES", "Text": "The ongoing COVID-19 pandemic has caused approximately 2,350,000 infections worldwide and killed more than 160,000 individuals .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "OBJECTIVES", "Text": "In Sainte-Anne Hospital ( GHU PARIS Psychiatrie & Neuroscience , Paris , France ) we have observed a lower incidence of symptomatic forms of COVID-19 among patients than among our clinical staff .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "incidence of symptomatic forms of COVID-19", "negation": "affirmed", "UMLS": {}, "start": 107, "end": 149}], "Observation": [{"term": "lower", "negation": "affirmed", "UMLS": {}, "start": 101, "end": 106}], "Count": []}, "Evidence Propositions": []}, {"Section": "OBJECTIVES", "Text": "This observation led us to hypothesize that psychotropic drugs could have a prophylactic action against SARS-CoV-2 and protect patients from the symptomatic and virulent forms of this infection , since several of these psychotropic drugs have documented antiviral properties .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "OBJECTIVES", "Text": "Chlorpromazine ( CPZ ) , a phenothiazine derivative , is also known for its antiviral activity via the inhibition of clathrin-mediated endocytosis .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "OBJECTIVES", "Text": "Recentin vitro studies have reported that CPZ exhibits anti-MERS-CoV and anti-SARS-CoV-1 activity .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "In this context , the ReCoVery study aims to repurpose CPZ , a molecule with an excellent tolerance profile and a very high biodistribution in the saliva , lungs and brain .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "CPZ", "negation": "affirmed", "UMLS": {}, "start": 55, "end": 58, "has_chemical": [{"text": "chlorpromazine", "maps_to": "C0033229:Prochlorpromazine", "start": 0, "end": 14}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "We hypothesize that CPZ could reduce the unfavorable course of COVID-19 infection among patients requiring respiratory support without the need for ICU care , and that it could also reduce the contagiousness of SARS-CoV-2 .", "Evidence Elements": {"Participant": [{"term": "respiratory support", "negation": "affirmed", "UMLS": {}, "start": 107, "end": 126}, {"term": "for ICU care", "negation": "negated", "UMLS": {}, "start": 144, "end": 156}], "Intervention": [{"term": "CPZ", "negation": "affirmed", "UMLS": {}, "start": 20, "end": 23, "has_chemical": [{"text": "chlorpromazine", "maps_to": "C0033229:Prochlorpromazine", "start": 0, "end": 14}], "has_relation": "N/A"}], "Outcome": [{"term": "unfavorable course of COVID-19 infection", "negation": "affirmed", "UMLS": {}, "start": 41, "end": 81}, {"term": "contagiousness of", "negation": "negated", "UMLS": {}, "start": 193, "end": 210}], "Observation": [{"term": "reduce", "negation": "negated", "UMLS": {}, "start": 30, "end": 36}, {"term": "reduce", "negation": "negated", "UMLS": {}, "start": 30, "end": 36}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "CPZ", "has_chemical": [{"text": "chlorpromazine", "maps_to": "C0033229:Prochlorpromazine", "start": 0, "end": 14}], "has_relation": "N/A"}, "Observation": "reduce", "Outcome": "unfavorable course of COVID-19 infection", "Count": ""}, {"Intervention": {"term": "CPZ", "has_chemical": [{"text": "chlorpromazine", "maps_to": "C0033229:Prochlorpromazine", "start": 0, "end": 14}], "has_relation": "N/A"}, "Observation": "reduce", "Outcome": "contagiousness of", "Count": ""}]}, {"Section": "METHODS", "Text": "For this purpose , we plan a pilot , multicenter , randomized , single blind , controlled , phase III therapeutic trial ( standard treatment vs . CPZ + standard treatment ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "CONCLUSION", "Text": "This repurposing of CPZ for its anti-SARS-CoV-2 activity could offer an alternative , rapid strategy to alleviate infection severity .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "CONCLUSION", "Text": "This repurposing strategy also avoids numerous developmental and experimental steps , and could save precious time to rapidly establish an anti-COVID-19 therapy with well-known , limited and easily managed side effects .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2020 L ' Enc\u00e9phale , Paris . Published by Elsevier Masson SAS .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "All rights reserved .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}